ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DMI) for Older Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (DF/HCC 18-124)
This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer.